{"id":61596,"date":"2024-03-03T06:01:14","date_gmt":"2024-03-03T06:01:14","guid":{"rendered":"https:\/\/medsname.com\/bicalumutide\/"},"modified":"2026-04-30T10:23:34","modified_gmt":"2026-04-30T10:23:34","slug":"bicalumutide","status":"publish","type":"product","link":"https:\/\/medsbase.com\/ro\/product\/bicalumutide\/","title":{"rendered":"Bicalumutide"},"content":{"rendered":"<p><!-- medsbase-tldr-answer --><\/p>\n<div style=\"background:#fff8e1;border-left:4px solid #f5a623;padding:18px 22px;margin:0 0 24px 0;border-radius:4px;\">\n<h3 class=\"wp-block-heading\" style=\"margin:0 0 8px 0;font-size:16px;font-weight:700;\">\u26a1 R\u0103spuns rapid \u2014 Ce este Bicalumutida?<\/h3>\n<p style=\"margin:0;\"><strong>Bicalumutide<\/strong> este un comprimat oral de la Cipla care con\u021bine <strong>bicalutamid\u0103 50 mg<\/strong> \u2014 un antagonist <strong>non-steroidian al receptorului de androgeni (anti-androgen)<\/strong> utilizat pentru <strong>cancer de prostat\u0103 avansat sau metastatic<\/strong>. Rol standard: utilizat \u00een combina\u021bie cu un <strong>agonist LHRH<\/strong> (goserelin\u0103, leuprorelin\u0103) pentru blocaj androgen combinat (BAC). Doz\u0103 standard: <strong>50 mg o dat\u0103 pe zi (cu agonist LHRH) sau 150 mg o dat\u0103 pe zi (monoterapie)<\/strong>. Efecte secundare principale: ginecomastie \u0219i sensibilitate mamara (frecvente), v\u0103rs\u0103turi de c\u0103ldur\u0103, hepatotoxicitate (monitorizare obligatorie a testelor hepatice), libido sc\u0103zut, pneumonit\u0103 intersti\u021bial\u0103 rar\u0103. <strong>Obligatoriu: teste hepatice de baz\u0103 + lunare pentru primele 4 luni, apoi periodice.<\/strong><\/p>\n<\/div>\n<div class=\"medsbase-trust-strip\" style=\"background:#f4f8fb;border:1px solid #d8e3eb;padding:12px 16px;margin:16px 0;border-radius:4px;font-size:14px;\">\n<strong>Ce beneficii ofer\u0103 MedsBase:<\/strong> Produc\u0103tor certificat WHO-GMP \u00b7 Ambalaj discret \u00b7 Livrare la nivel mondial \u00b7 Peste 1.400 de recenzii verificate <a href=\"https:\/\/medsbase.com\/ro\/reviews\/\">ale clien\u021bilor<\/a>\n<\/div>\n<p class=\"medsbase-reship-line\" style=\"font-size:14px;color:#444;margin:8px 0 18px;\">\ud83d\udce6 Fiecare comand\u0103 este acoperit\u0103 de politica noastr\u0103 de <a href=\"https:\/\/medsbase.com\/ro\/medsbase-re-shipment-assurance-policy\/\"><strong>Politica noastr\u0103 de Reexpediere Garantat\u0103<\/strong><\/a> \u2014 dac\u0103 coletul dumneavoastr\u0103 nu sose\u0219te \u00een 20 de zile lucr\u0103toare, \u00eel relivr\u0103m.<\/p>\n<div style=\"background:#fff3f3;border-left:4px solid #d9534f;padding:14px 18px;margin:0 0 24px 0;border-radius:4px;font-size:14px;\"><strong>\u26a0 Supraveghere specializat\u0103 necesar\u0103.<\/strong> Medicamentele pentru cancer trebuie prescrise de un oncolog tratant, cu un diagnostic confirmat, stadializare ini\u021bial\u0103 \u0219i un plan de tratament definit. Nu \u00eencepe\u021bi, nu opri\u021bi, nu modifica\u021bi doza \u0219i nu utiliza\u021bi medicamente pentru cancer \u00een afara unui plan de \u00eengrijire condus de oncologie. Majoritatea medicamentelor pentru cancer necesit\u0103 monitorizare regulat\u0103 prin analize de s\u00e2nge (hemoleucogram\u0103, teste hepatice, func\u021bie renal\u0103), sunt absolut contraindicate \u00een sarcin\u0103 \u0219i au interac\u021biuni medicamentoase semnificative.<\/div>\n<h2 class=\"wp-block-heading\">Ce este Bicalumutida?<\/h2>\n<p>Bicalumutida este un comprimat oral de la Cipla care con\u021bine <strong>bicalutamid\u0103 50 mg<\/strong>. Bicalutamida este un antiandrogen non-steroidian care blocheaz\u0103 competitiv receptorul de androgeni \u00een celulele cancerului de prostat\u0103, inhib\u00e2nd efectul proliferativ al testosteronului \u0219i dihidrotestosteronului (DHT). Este utilizat\u0103 \u00een <strong>cancer de prostat\u0103 avansat sau metastatic<\/strong>, aproape \u00eentotdeauna \u00een combina\u021bie cu un agonist LHRH (goserelin, leuprorelin, triptorelin) pentru <strong>blocarea androgen\u0103 combinat\u0103 (CAB)<\/strong>.<\/p>\n<h2 class=\"wp-block-heading\">Cum func\u021bioneaz\u0103 Bicalumutida?<\/h2>\n<p>Cre\u0219terea cancerului de prostat\u0103 este determinat\u0103 de semnalizarea receptorului de androgeni. Terapia standard de deprivare androgen\u0103 (ADT) suprima produc\u021bia de androgeni ovarici prin agonii LHRH. Cu toate acestea, glandele suprarenale continu\u0103 s\u0103 produc\u0103 aproximativ 10% din androgenii totali ai corpului, iar semnalul rezidual este suficient pentru a determina progresia bolii la mul\u021bi pacien\u021bi. Bicalumutida blocheaz\u0103 receptorul de androgeni \u00een sine, astfel \u00eenc\u00e2t androgenii suprarenali reziduali nu pot semnaliza \u2014 produc\u00e2nd o blocare androgen\u0103 mai complet\u0103.<\/p>\n<ul>\n<li><strong>Antagonist competitiv al receptorului androgen<\/strong> \u2014 se leag\u0103 de AR \u0219i \u00eempiedic\u0103 testosteronul\/DHT s\u0103-l activeze.<\/li>\n<li><strong>Timp de \u00eenjum\u0103t\u0103\u021bire lung (~6 zile)<\/strong> \u2014 administrare oral\u0103 o dat\u0103 pe zi.<\/li>\n<li><strong>Utilizat pentru a preveni \u201cexacerbarea tumoral\u0103\u201d<\/strong> la \u00eenceperea terapiei cu agonist LHRH - cre\u0219terea ini\u021bial\u0103 de testosteron indus\u0103 de LHRH poate agrava temporar boala, iar tratamentul prealabil cu antiandrogen blocheaz\u0103 acest efect.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Utiliz\u0103ri \u0219i indica\u021bii<\/h2>\n<ul>\n<li><strong>Blocare androgen\u0103 combinat\u0103 (CAB)<\/strong> \u00een cancerul de prostat\u0103 avansat sau metastatic (cu agonist LHRH)<\/li>\n<li><strong>Prevenirea exacerb\u0103rii tumorale<\/strong> la ini\u021bierea agonistului LHRH (pre-tratament 2\u20134 s\u0103pt\u0103m\u00e2ni)<\/li>\n<li><strong>Monoterapie 150 mg\/zi<\/strong> \u00een cancerul de prostat\u0103 local avansat, nemetastatic (alternativ\u0103 la agonistul LHRH pentru pacien\u021bii care prioritizeaz\u0103 p\u0103strarea func\u021biei sexuale)<\/li>\n<li><strong>Dup\u0103 recuren\u021b\u0103 biochimic\u0103<\/strong> ca parte a schemelor de deprivare androgen\u0103 intermitent\u0103 sau continu\u0103<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Doza de Bicalumutida \u0219i cum se administreaz\u0103<\/h2>\n<p>Doza standard: <strong>50 mg o dat\u0103 pe zi (cu agonist LHRH) sau 150 mg o dat\u0103 pe zi (monoterapie)<\/strong>.<\/p>\n<ol>\n<li><strong>O dat\u0103 pe zi, la aceea\u0219i or\u0103 \u00een fiecare zi.<\/strong> Cu sau f\u0103r\u0103 alimente.<\/li>\n<li><strong>\u00cenghi\u021bi\u021bi \u00eentreaga tablet\u0103 cu ap\u0103.<\/strong><\/li>\n<li><strong>Monitorizare obligatorie:<\/strong> teste hepatice ini\u021biale (AST, ALT) \u0219i PSA. Repeta\u021bi testele hepatice <strong>lunar \u00een primele 4 luni<\/strong>, apoi la fiecare 3\u20136 luni. PSA la fiecare 3 luni. \u00centrerupe\u021bi \u0219i investiga\u021bi dac\u0103 AST\/ALT &gt; de 3 ori limita superioar\u0103 a normalului.<\/li>\n<li><strong>Prevenirea flare-ului tumoral pre-LHRH-agonist:<\/strong> \u00eencepe\u021bi Bicalumutida cu 2\u20134 s\u0103pt\u0103m\u00e2ni \u00eenainte de ini\u021bierea agonistului LHRH, continua\u021bi cel pu\u021bin o lun\u0103 dup\u0103.<\/li>\n<li><strong>Nu \u00eentrerupe\u021bi f\u0103r\u0103 instruc\u021biuni de la oncolog.<\/strong><\/li>\n<\/ol>\n<h2 class=\"wp-block-heading\">Efecte secundare ale Bicalumutidei<\/h2>\n<p><strong>Frecvente:<\/strong><\/p>\n<ul>\n<li>Ginecomastie \u0219i sensibilitate mamara (40\u201370% cu monoterapie; mai pu\u021bin cu CAB)<\/li>\n<li>V\u0103rs\u0103turi de c\u0103ldur\u0103<\/li>\n<li>Sc\u0103derea libidoului \u0219i disfunc\u021bia erectil\u0103<\/li>\n<li>Oboseal\u0103, astenie<\/li>\n<li>Diarree (\u00een special la flutamid\u0103)<\/li>\n<li>Disconfort gastrointestinal u\u0219or<\/li>\n<\/ul>\n<p><strong>Important \u2014 monitorizare obligatorie:<\/strong><\/p>\n<ul>\n<li><strong>Hepatotoxicitate<\/strong> \u2014 poate fi sever\u0103 \u0219i imprevizibil\u0103. \u00centrerupe\u021bi imediat la apari\u021bia icterului, urinei \u00eentunecate, oboselii severe sau AST\/ALT &gt; 3\u00d7 ULN. Majoritatea cazurilor apar \u00een primele 4 luni.<\/li>\n<li>Pneumonit\u0103 intersti\u021bial\u0103 rar\u0103 \u2014 tuse de debut nou, dispnee<\/li>\n<\/ul>\n<p><strong>Rare:<\/strong> anemie hemolitic\u0103, fotosensibilitate, reac\u021bii cutanate severe.<\/p>\n<h2 class=\"wp-block-heading\">Avertismente \u0219i precau\u021bii<\/h2>\n<ul>\n<li><strong>Sarcin\u0103 \u0219i al\u0103ptare:<\/strong> nu se aplic\u0103 (indica\u021bie doar pentru b\u0103rba\u021bi), dar antiandrogenii sunt fetotoxici dac\u0103 sunt lua\u021bi din gre\u0219eal\u0103 \u00een timpul sarcinii.<\/li>\n<li><strong>Func\u021bia hepatic\u0103:<\/strong> teste hepatice obligatorii lunare pentru primele 4 luni. \u00centrerupe\u021bi la AST\/ALT &gt; 3\u00d7 ULN.<\/li>\n<li><strong>Diabet:<\/strong> poate agrava controlul glicemic.<\/li>\n<li><strong>Cardiovascular:<\/strong> ADT \u00een general este asociat cu cre\u0219terea riscului de evenimente cardiovasculare. Optimiza\u021bi factorii de risc modificabili.<\/li>\n<li><strong>Profilaxia ginecomastiei:<\/strong> doze mici de tamoxifen 10\u201320 mg\/zi sau radioterapie profilactic\u0103 a s\u00e2nului reduc inciden\u021ba (specialist).<\/li>\n<li><strong>Conducere:<\/strong> precau\u021bie \u2014 oboseala \u0219i ame\u021belile pot afecta capacitatea de a conduce.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Interac\u021biuni medicamentoase<\/h2>\n<table style=\"border-collapse:collapse;width:100%;margin:12px 0;\">\n<thead>\n<tr style=\"background:#2c7cb0;color:#fff;\">\n<th style=\"padding:10px;border:1px solid #ddd;\">Combina\u021bi cu<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">Efect<\/th>\n<th style=\"padding:10px;border:1px solid #ddd;\">Ce s\u0103 face\u021bi<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Warfarin \u0219i alte anticoagulante cumarinice<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Cre\u0219tere semnificativ\u0103 a INR \u2014 risc de s\u00e2ngerare<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Verifica\u021bi INR s\u0103pt\u0103m\u00e2nal la \u00eenceput. Reduce\u021bi doza de warfarin cu 30\u201350%.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Inhibitori CYP3A4 (efect minor)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Cre\u0219terea nivelurilor de bicalutamid\u0103<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Monitoriza\u021bi hepatotoxicitatea.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Agoni\u0219ti LHRH (goserelin, leuprorelin)<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Combina\u021bie standard \u2014 blocaj androgen combinat<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Regim standard CAB.<\/td>\n<\/tr>\n<tr>\n<td style=\"padding:10px;border:1px solid #ddd;\">Alcool<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Hepatotoxicitate aditiv\u0103<\/td>\n<td style=\"padding:10px;border:1px solid #ddd;\">Limita\u021bi consumul de alcool \u00een timpul tratamentului.<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2 class=\"wp-block-heading\">Depozitare<\/h2>\n<ul>\n<li>P\u0103stra\u021bi la temperatura camerei, 15\u201325\u00b0C, \u00een blisterul original.<\/li>\n<li>P\u0103stra\u021bi departe de copii, femei \u0219i animale de companie \u2014 antiandrogenii sunt fetotoxici.<\/li>\n<\/ul>\n<h2 class=\"wp-block-heading\">Alternative conexe pe MedsBase<\/h2>\n<p>Alte medicamente oncologice disponibile \u00eempreun\u0103 cu acest produs:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/bdenza\/\"><strong>Bdenza (enzalutamid\u0103 40 mg)<\/strong><\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/cytomid\/\"><strong>Cytomid (flutamid\u0103 250 mg)<\/strong><\/a><\/li>\n<\/ul>\n<p><a href=\"https:\/\/medsbase.com\/ro\/anti-cancer-medication\/\">R\u0103sfoi\u021bi toate medicamentele anti-cancer \u2192<\/a><\/p>\n<h2 id=\"faqs\">\u00centreb\u0103ri frecvente<\/h2>\n<h3 class=\"wp-block-heading\">De ce este Bicalutamida de obicei combinat\u0103 cu un agonist LHRH?<\/h3>\n<p>Agoni\u0219tii LHRH (goserelin\u0103, leuprorelin\u0103) suprima produc\u021bia testicular\u0103 de androgeni, dar glandele suprarenale continu\u0103 s\u0103 produc\u0103 aproximativ 10% din androgenii corpului care pot stimula cre\u0219terea cancerului de prostat\u0103. Bicalutamida blocheaz\u0103 receptorul de androgen \u00eensu\u0219i, astfel \u00eenc\u00e2t androgenii suprarenali nu pot transmite semnale. Combina\u021bia se nume\u0219te <strong>blocarea androgen\u0103 combinat\u0103 (CAB)<\/strong> \u0219i produce o suprresie mai profund\u0103 a androgenilor dec\u00e2t agonistul LHRH singur \u00een boala avansat\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Ce este \u201ctumour flare\u201d \u0219i de ce \u00eel previne Bicalutamida?<\/h3>\n<p>C\u00e2nd \u00eencepe terapia cu agonist LHRH, hipofiza este ini\u021bial stimulat\u0103 \u0219i testosteronul cre\u0219te brusc timp de 1\u20132 s\u0103pt\u0103m\u00e2ni \u00eenainte ca downregularea s\u0103 intre \u00een vigoare. La pacien\u021bii cu povar\u0103 semnificativ\u0103 a bolii (metastaze osoase, obstruc\u021bie urinar\u0103, risc de compresiune a m\u0103duvei spin\u0103rii), aceast\u0103 cre\u0219tere tranzitorie a testosteronului poate agrava simptomele \u00een mod acut. \u00cenceperea Bicalutamidei cu 2\u20134 s\u0103pt\u0103m\u00e2ni \u00eenainte de agonistul LHRH blocheaz\u0103 receptorul \u0219i previne flare-ul.<\/p>\n<h3 class=\"wp-block-heading\">Cum se gestioneaz\u0103 ginecomastia?<\/h3>\n<p>Tendin\u021ba mamar\u0103 \u0219i ginecomastia afecteaz\u0103 40\u201370% dintre pacien\u021bii sub monoterapie cu bicalutamid\u0103 la doze mai mari. Op\u021biuni de profilaxie: <strong>tamoxifen la doz\u0103 mic\u0103 10\u201320 mg\/zi<\/strong> (cele mai multe dovezi) sau <strong>radioterapie profilactic\u0103 pentru cancerul de s\u00e2n<\/strong> ca o singur\u0103 frac\u021biune de 8\u201312 Gy \u00eenainte de a \u00eencepe terapia anti-androgen\u0103. Discuta\u021bi cu oncologul \u00eenainte de a \u00eencepe dac\u0103 preocup\u0103rile cosmetice sunt semnificative.<\/p>\n<h3 class=\"wp-block-heading\">Ce analize de s\u00e2nge am nevoie?<\/h3>\n<p><strong>Obligatoriu:<\/strong> analizele hepatice ini\u021biale (AST, ALT) \u0219i PSA. Apoi analizele hepatice <strong>lunar \u00een primele 4 luni<\/strong>, apoi la fiecare 3\u20136 luni. PSA la fiecare 3 luni. \u00centrerupe\u021bi Bicalutamida imediat \u0219i contacta\u021bi oncologul dvs. dac\u0103 AST\/ALT &gt; 3\u00d7 ULN sau pentru orice icter, urin\u0103 \u00eenchis\u0103 sau oboseal\u0103 sever\u0103.<\/p>\n<h3 class=\"wp-block-heading\">Pot s\u0103 consum alcool \u00een timpul tratamentului cu Bicalutamid\u0103?<\/h3>\n<p>Limita\u021bi consumul de alcool \u2014 at\u00e2t alcoolul, c\u00e2t \u0219i bicalutamida sunt hepatotoxice, iar combina\u021bia amplific\u0103 riscul de leziuni hepatice severe induse de medicamente. Cantit\u0103\u021bi mici ocazionale sunt de obicei tolerabile; consumul abundent sau zilnic ar trebui evitat pe tot parcursul tratamentului.<\/p>\n<h3 class=\"wp-block-heading\">Bicalutamid\u0103 vs flutamid\u0103 vs enzalutamid\u0103 \u2014 care este diferen\u021ba?<\/h3>\n<p>Toate trei sunt antiandrogene orale pentru cancerul de prostat\u0103. <strong>Bicalutamida:<\/strong> o dat\u0103 pe zi, bine tolerat\u0103, alegerea standard de prim\u0103 genera\u021bie. <strong>Flutamida:<\/strong> de trei ori pe zi, risc mai mare de diaree \u0219i hepatotoxicitate \u2014 \u00een mare parte \u00eenlocuit\u0103 de bicalutamid\u0103. <strong>Enzalutamide:<\/strong> de a doua genera\u021bie, mai puternic\u0103, utilizat\u0103 pentru boala rezistent\u0103 la castrare (dup\u0103 e\u0219ecul CAB) \u2014 vezi <a href=\"https:\/\/medsbase.com\/ro\/bdenza\/\">Bdenza<\/a>.<\/p>\n<h3 class=\"wp-block-heading\">Bicalumutide \u00eemi va afecta inima?<\/h3>\n<p>Monoterapia cu anti-androgeni are un efect cardiovascular direct minimal, dar terapia mai ampl\u0103 de deprivare androgen\u0103 (agonist LHRH + anti-androgen) este asociat\u0103 cu un risc crescut de evenimente cardiovasculare, inclusiv infarct miocardic \u0219i accident vascular cerebral. Optimiza\u021bi factorii de risc cardiovascular: controlul tensiunii arteriale, statin\u0103 dac\u0103 exist\u0103 hiperlipidemie, renun\u021barea la fumat, exerci\u021bii fizice, gestionarea greut\u0103\u021bii.<\/p>\n<h3 class=\"wp-block-heading\">Pot s\u0103 opresc Bicalumutide dac\u0103 PSA r\u0103m\u00e2ne sc\u0103zut?<\/h3>\n<p>Discuta\u021bi cu oncologul dumneavoastr\u0103. \u00cen unele protocoale de CAB intermitent, CAB este \u00eentrerupt atunci c\u00e2nd PSA este suprimat sub prag \u0219i reluat c\u00e2nd PSA cre\u0219te \u2014 acest lucru poate reduce efectele secundare f\u0103r\u0103 a compromite supravie\u021buirea. Nu opri\u021bi niciodat\u0103 unilateral \u2014 monitorizarea PSA \u0219i momentul relu\u0103rii sunt critice.<\/p>\n<div style=\"background:#f4f8fb;border:1px solid #d6e4ec;padding:12px 18px;margin:14px 0;border-radius:4px;font-size:14px;color:#3a5160;text-align:center;\">\n<strong>\ud83d\udd12 Checkout criptat<\/strong> \u00b7 <strong>\ud83d\udcb3 Procesor verificat<\/strong> \u00b7 <strong>\ud83d\ude9a Livrare worldwide<\/strong> \u00b7 <strong>\u2b50 4,9\/5 de la peste 1.400 de clien\u021bi<\/strong>\n<\/div>\n<p><!-- medsbase-why-order --><\/p>\n<h3>De ce s\u0103 comanzi de la MedsBase<\/h3>\n<p>Fiecare lot este procurat de la un <strong>produc\u0103tor certificat WHO-GMP<\/strong>. Comenzile sunt expediate \u00een ambalaje simple, f\u0103r\u0103 marc\u0103, de la partenerii no\u0219tri de onorare \u0219i acoperite de <a href=\"\/ro\/medsbase-re-shipment-assurance-policy\/\">Politica noastr\u0103 de Reexpediere Garantat\u0103<\/a>: dac\u0103 un colet nu ajunge \u00een 20 de zile lucr\u0103toare, trimitem gratuit o nou\u0103 comand\u0103, f\u0103r\u0103 \u00eentreb\u0103ri.<\/p>\n<p><!-- medsbase-related-alts-v1 --><\/p>\n<h3 class=\"wp-block-heading\">Alternative conexe<\/h3>\n<p>Alte produse din <strong>Afec\u021biuni cronice<\/strong> pe care clien\u021bii le vizualizeaz\u0103 de asemenea:<\/p>\n<ul>\n<li><a href=\"https:\/\/medsbase.com\/ro\/riborea\/\">Riborea<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/bacloheal\/\">Bacloheal<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/amlode\/\">Amlode<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/nicerbium\/\">Nicerbium<\/a><\/li>\n<li><a href=\"https:\/\/medsbase.com\/ro\/lipril-h\/\">Lipril-H<\/a><\/li>\n<\/ul>","protected":false},"excerpt":{"rendered":"<p>\u2705 Trateaz\u0103 cancerul de prostat\u0103<br \/>\n\u2705 Blocheaz\u0103 hormonii masculini<br \/>\n\u2705 \u00cencetine\u0219te cre\u0219terea tumorii<br \/>\n\u2705 \u00cembun\u0103t\u0103\u021be\u0219te ratele de supravie\u021buire<br \/>\n\u2705 Reduce simptomele cancerului<\/p>\n<p>Bicalumutide con\u021bine Bicalutamide.<\/p>","protected":false},"featured_media":61597,"comment_status":"closed","ping_status":"open","template":"","meta":[],"product_brand":[],"product_cat":[3595,3614,3141,3223,3342],"product_tag":[5066,5067],"class_list":{"0":"post-61596","1":"product","2":"type-product","3":"status-publish","4":"has-post-thumbnail","6":"product_cat-anti-cancer-medication","7":"product_cat-bladder-prostate","8":"product_cat-category-overview","9":"product_cat-chronic-conditions","10":"product_cat-general-health","11":"product_tag-bicalumutide","12":"product_tag-bicalutamide","14":"first","15":"instock","16":"shipping-taxable","17":"purchasable","18":"product-type-variable","19":"has-default-attributes"},"acf":[],"_links":{"self":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product\/61596","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/comments?post=61596"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media\/61597"}],"wp:attachment":[{"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/media?parent=61596"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_brand?post=61596"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_cat?post=61596"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/medsbase.com\/ro\/wp-json\/wp\/v2\/product_tag?post=61596"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}